TYME Granted U.S. Patent Claims Treat COVID-19 Infections
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections
TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19.
Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat.
TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19.
TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication.
finance.yahoo.com/news/tyme-granted-u-patent-claims-130000101.html
TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19.
Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat.
TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19.
TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication.
finance.yahoo.com/news/tyme-granted-u-patent-claims-130000101.html
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.